NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report sent to investors on Monday morning. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NBY opened at $0.62 on Monday. The firm has a 50 day simple moving average of $0.67 and a 200 day simple moving average of $1.49. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $11.45. The company has a market cap of $3.05 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.